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ARSTRACT 
Objectives: To determine the incidence of toxoplasmic 
encephalitis (TE) in patients with acquired immunodeficiency 
syndrome (AIDS) in Yugoslavia and to analyze the contribution 
of sex, age, human immunodeficiency virus (HIV) transmission 
risk factors, CD4+ T-cell count, and systemic Pneumocystis 
carinii pneumonia (PCP) prophylaxis as risk factors for the devel- 
opment of TE. 
Design: Retrospective chart review of 288 (72%) of the 399 
AIDS patients diagnosed in Yugoslavia during the 5year period 
1991 to 1995. Inclusion criteria included serology for toxo- 
plasmosis performed prior to the TE episode. 
Results: Toxoplasma gondii-specific IgG antibodies were 
detected in 127 of the 288 AIDS patients (44.1%) tested sero- 
logically (including all with neurologic abnormalities). A total of 
31 patients developed TE, indicating a TE overall attack rate 
of 7.8%. Of these, 29 TE episodes occurred in the T; gondii- 
seropositive patients (22.8%), significantly more often than in 
the T: go&ii-seronegative (x2 = 34.423, P < 0.005), among 
which TE occurred in two (2/l 61, 1.24%). By survival analysis, 
the cumulative incidence of TE in the T: gondii-seropositive 
patients was 32.7% for 60 months (30% for 24 months). 
Although not associated with age, sex, or HIV transmission 
risk factor, the risk for TE increased with the decrease in the 
CD4+ T-cell count (relative risk [RR] = 0.276, 95% confidence 
interval [Cl] = 0.198-0.673, P = 0.0013), and was reduced in 
patients on systemic PCP prophylaxis (RR = 0.222, 95% Cl = 
0.068-0.642, P = 0.006). 
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Conclusions: In areas of high exposure to 7: gondii, such as 
Yugoslavia, timely serology for toxoplasmosis in patients with 
AIDS and subsequent drug prophylaxis to prevent reactivation 
in seropositive patients is recommended. 
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Disease due to infection with the protozoan parasite Toxo- 
plasma gondii is a major complication of human 
immunodeficiency virus (HIV)-induced immunosuppres- 
sion and the leading cause of focal cerebral lesions in 
patients with acquired immunodeficiency syndrome 
(AIDS). l Although extracerebral toxoplasmosis has been 
reported inAIDS,* the most common clinical presentation 
is toxoplasmic encephalitis (TE), which is fatal unless 
promptly treated. 
In the HIV-infected patient, disease due to T.gondii 
infection is generally considered to represent reactiva- 
tion of chronic (latent) infection. Thus, the risk for devel- 
oping TE in a given population largely depends on the 
prevalence of latent toxoplasmosis in the respective area. 
Among patients with AIDS who have evidence of prior 
infection with Tgondii, a significant portion will even- 
tually develop TE; that proportion has ranged from 30% 
in the United States to 50% in Europe andAfrica.‘s3 
The objectives of this study thus were to determine 
the risk for the development of TE in Yugoslavia and to 
assess the contribution of certain demographic, epi- 
demiologic, and laboratory parameters as TE risk factors 
in the Yugoslav AIDS population. 
MATERIAL AND METHODS 
Patient Population 
By December 31, 1995, AIDS was diagnosed in 530 
patients (41 lM, 119F) seen at the HIV/AIDS Center at the 
Institute for Infectious and Tropical Diseases in Belgrade, 
the single institution in Yugoslavia (comprising Serbia and 
Montenegro) to which AIDS patients are referred. Of these, 
399 were diagnosed during the 5year period between 
January I, 1991 and December 31,1995.Diagnosis ofAIDS 
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was established following the 1987 revised Centers for 
Disease Control (CDC) case definition criteria.* Systematic 
screening for toxoplasmosis, initiated in January 1991, 
involved 288 (72%) consecutive patients at some stage of 
the disease (CDC grades II-IV) who consented to the test- 
ing.These included all with neurologic abnormalities.The 
charts and records were reviewed and analyzed with 
respect to different parameters. No patient received pro- 
phylaxis specifically to prevent toxoplasmosis; however, 
59 patients received systemic primary or secondary Pneu- 
mocystis carinii pneumonia (PCP) prophylaxis, shown to 
be beneficial against reactivation of latent toxoplasmosis.5-7 
This involved trimethoprim-sulfamethoxazole (I~O/SOO 
mg, 3 times a week) in 37, and sulfadoxine-pyrimethamine 
(500/25 mg, once a week) in 22 patients. 
Toxoplasmosis Serology 
Toxoplasma gondii-specific IgG antibody was detected 
by the Sabin-Feldman test (WI) modified by Desmonts 
into the lysis test, or the IgG-enzyme immunoassay GgG 
EIA).The SFT was performed using tachyzoites of the RH 
strain as described elsewhere.8 Ten-fold serial dilutions 
of sera were tested starting at l:lO.The fmal serum dilu- 
tion at which more than 50% of parasites were lysed was 
considered the serum titer. A titer of 1: 10 was the cutoff 
value. Commercial IgGEIA (OrganonTeknika, the Nether- 
lands) was performed according to the manufacturer’s 
instructions, and the results were interpreted by means 
of a calibration curve, with a titer of 1: 100 as the cutoff. 
The immunosorbent agglutination assay (ISAgA) (bio- 
Merieux, Charbonnieres-les-Bains, France) was used to 
detect i? gondii-specific IgM antibody The results were 
expressed as an index of the degree of agglutination read 
for the three volumes of antigen used on a scale from 0 
to 12. A score of higher than 8 was considered positive. 
Diagnosis of Cerebral Toxoplasmosis 
A presumptive TE diagnosis was established on the basis 
of both neuroradiographic (computerized tomography 
[CT] scan or magnetic resonance imaging [MRI]) find- 
ings of a typical space-occupying lesion (hypodense zone 
with ring enhancement after intravenous contrast admin- 
istration) in a patient with neurologic disorders, and clin- 
ical and neuroradiographic improvement following 
specific anti-toxoplasmosis drug treatment with no other 
concomitant anti-inflammatory therapy. No brain biop- 
sies or autopsies were performed. 
Statistics 
The difference in the occurrence of TE between the 1: 
gondii-seropositive and -seronegative patient groups was 
analyzed by chi-square test. The estimated probability of 
toxoplasmosis-free survival and estimated mean survival 
time in the seropositive patients were evaluated by the 
Kaplan-Meier product limit method.The contribution of 
particular TE risk factors as independent variables was 
analyzed by the Cox proportional hazards regression 
model, using both the univariate and multivariate 
approaches.The difference between the curves was eval- 
uated by Peto’s log rank test.9 The level of statistical sig- 
nificance was 5%. 
RESULTS 
Prevalence of Latent Toxoplasmosis 
Serologic tests for toxoplasmosis were performed in 288 
AIDS patients of the 399 registered during the period 
1991 to 1995 inyugoslavia (72.2%), including all with 
symptoms and signs of neurologic abnormalities. Toxo- 
plasma gondii-specific IgG antibody was detected in 127 
patients, whereas specific IgM was not detected in any, 
even with a technique as sensitive as the ISAgA, indicat- 
ing a prevalence of latent toxoplasmosis in the AIDS pop- 
ulation of 44.1%. 
Frequency Rate of Toxoplasmic Encephalitis 
A total of 31 patients developed TE (only a first event 
was taken into account), indicating a TE attack rate of 
7.8% in all AIDS patients registered within the study 
period. Of the 3 1 TE episodes, 29 occurred in 7: gondii- 
seropositive patients (29/127,22.8%).The remaining two 
developed in T. gondii-seronegative patients (2/161, 
1.24%) and were diagnosed on the basis of clinical pre- 
sentation, neuroradiography and prompt response to anti- 
toxoplasmosis drug treatment. Since serologic tests were 
not performed in undiluted serum, the presence of spe- 
cific antibody below the cutoff level was not ruled out. 
Obviously, the difference in the TE frequency rates 
between the groups of Zgondii-seropositive and -seroneg- 
ative patients was highly significant (x2 = 34.423, P < 
O.OOS).The latter finding, as well as the small size of the 
group of rgondii-seronegative TE patients, prompted fur- 
ther analysis to be restricted to the rgondii-seropositive 
patients. 
By survival analysis, the estimated probability of toxo- 
plasmosis-free survival in the 1: goqdii-seropositive 
patients for 60 months was 67.3% (Figure l), that is, the 
TE cumulative incidence was 32.7% (30% for 24 months). 
Analysis of Risk Factors for Toxoplasmic Encephalitis 
Basic characteristics of the Z?gondii-seropositive patients 
with and without TE are presented in Table 1. Statistical 
analysis failed to show the association of TE and demo- 
graphic factors such as sex (P = 0.495) and age 
(P = 0.157). Furthermore, an increased risk for TE was 
not associated with any HIV transmission risk factor: intra- 
venous drug abuse (P = 0.112) blood or blood product 
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Figure 1. The estimated probability of toxoplasmosis-free survival 
(Kaplan-Meier product limit method) in 127 T: go&ii-seropositive 
patients with AIDS. 
transfusion (P = 0.758) homosexual contacts (P = 0.219) 
and heterosexual contacts or unknown risk factor 
(P = O.S58).To analyze the CD4+ T-cell number as a risk 
factor for TE, the CD4+ T-cell counts (available in 74 
patients) were stratified into four levels as follows: I, 
below 50 X 10h/L; II, 50-200 X 106/L; III, 200-500 X 
106/L; and IV, above 500 X lob/L. The estimated toxo- 
plasmosis-free mean survival times in the respective strata 
were: I, 14.6 months (95% confidence interval [CI] = 
9.5-19.7); II, 48.5 months (95% CI = 39.5-57.4); III, 51.9 
Table 1. Basic Characteristics of 
Toxoplasma gondii-Seropositive Patients with 




Age (mean and range, y) 
Risk group 
Intravenous drug users 
Blood transfusion recipients 
Homosexuals 
Heterosexuals and unknown 
Prophylaxis, received (n = 59) 
Time of prophylaxis 
(mean and range, mo) 
CD4+ T-cell count (n = 74) 
(median and range, xl OVL) 
Observation period 
Until death or Dec. 31, 1995 
(mean and range, mo) 
TE Patients Non-TE Patients 
(n = 29) (n = 98) 
22 (75.9%) 67 (68.4%) 
7 (24.1%) 31 (31.6%) 
35.9 (22-56) 34.7 (8-60) 
20 (69.0%) 45 (45.9%) 
3 (10.3%) 12 (12.3%) 
1 (35%) 21 (21.4%) 
5 (17.2%) 20 (20.4%) 
10 (34.5%) 49 (50%) 
8.5 (i-l 9.5) 20.3 (l-60) 
30 (8-280) 190 (3-1110) 
6.9 (i-24) 21.9 (l-60) 
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Figure 2. The estimated probability of toxoplasmosis-free sumival 
(Kaplan-Meier product limit method) in 74 T: gondii-seropositive patients 
with AIDS with respect to CD4+ T-cell counts. P = value of log rank 
test used to compare the difference among the curves. 
months (95% CI = 43.4-60.4); and Iv, greater than 60 
months.The estimated probability of toxoplasmosis-free 
survival differed significantly between the strata 
(P = 0.0028, log rank test) (Figure 2). 
By the Cox proportional hazards model, the CD4+ 
T-cell count was shown to be a strong independent 
predictor (relative risk [RR] = 0.276, 95% CI = 
0.198-0.673, P = 0.0013). Importantly, an increased risk 
of TE (RR = 0.861) existed already at CD4+ counts 
between 200 and 500 X 106/L. Of note, the three 
Figure 3. The estimated probability of toxoplasmosis-free survival in 
127 T: gondii-seropositive patients with AIDS with respect to P carinii 
pneumonia prophylaxis. P = value of log rank test used to compare 
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patients in this subgroup, of whom none received toxo- 
plasmosis-effective prophylaxis, developed TE at CD4+ 
counts of 204,223, and 280 X lO(‘/L, respectively. 
Fifty-nine of the 127 seropositive patients received 
systemic PCP prophylaxis regularly for at least 1 month 
(before developing TE, death, or end of study). Of these, 
10 (16.9%) developed TE versus 19 (27.9%) of the 68 
who did not receive prophylaxis.The Kaplan-Meier esti- 
mated time of toxoplasmosis-free survival was 51.5 
months (95% CI = 46.0-56.9) in the patients on pro- 
phylaxis as opposed to 32.7 months (95% CI = 23.7-41.8) 
in the othersThe difference in the estimated probability 
of toxoplasmosis-free survival between the subgroups 
was highly significant (P = 0.0006, log rank test) (Figure 
3). Finally, Cox analysis showed that PCP prophylaxis con- 
tributed a strong positive prognostic factor (RR = 0.222, 
95% CI = 0.068-0.642, P = 0.006). 
DISCUSSION 
The number of known HIV-positive individuals in 
Yugoslavia amounted to approximately 2000 by the end 
of 1995, while at the same time the World Health Orga- 
nization estimated about 5000 individuals were infected.l’ 
By December 3 1) 1995,530 patients were diagnosed with 
AIDS, of which 399 were diagnosed since January 1,199l. 
Thus, this study of the risk for the development ofTE in 
AIDS patients involving more than half (288/530,54.3%) 
of the country’s total AIDS population and 72% of all AIDS 
patients within the study period, is highly representative 
of the country 
The prevalence of latent toxoplasmosis as indicated 
by positive Tgondii serology was 44.1%.This is actually 
somewhat lower than the prevalence reported in 
Yugoslavia where, in women of reproductive age, it was 
about 50%,11 and in a general population 58%.r2 In addi- 
tion to the time gap between these and the present inves- 
tigation, possible explanations include (1) the wide age 
range of the AIDS patients (8-60 y), with more below 
age 20, where the prevalence of infection is generally 
lower, than above age 40; and (2) the inability of some to 
mount an adequate humoral immunologic response to Z? 
gondii because of their immunosuppression at the time 
of the actual sampling.That the latter may be true is sup- 
ported by the occurrence of well-documentedTE in two 
T. gondii-seronegative patients, both of whom had 
extremely low CD4+ T-cell counts (20 and 30 X lob/L, 
respectively) at the time of the episode. Indeed, it is esti- 
mated that less than 3% of allTE cases develop in seroneg- 
ative AIDS patients,l-7 which obviously calls for early T. 
gondii serology, performed as soon as HIV infection is 
diagnosed. Nevertheless, the extremely low risk for devel- 
oping TE in T. gondii-seronegative patients (1.24%) 
confirms the high predictive value of a negative toxo- 
plasmosis serology. 13z1* 
Both the overall frequency of TE of 7.8% and that in 
the Tgondii-seropositive patients of 22.8% found in the 
study patient population fall within the reported figures.1,15 
Furthermore, the estimated probability of TE of 30% for 2 
years is similar to the much quoted finding of 26% for the 
same period in the United States.16The difference may be 
due to sampling fluctuations. However, the fmding in this 
study is still significantly below the cumulative incidence 
of 64% for 2 years in Tgondii-seropositive HIV infected 
patients reported in the geographically proximate region 
of the AustrianTyrol.17 The fact that the latter patients did 
not receive systemic PCP prophylaxis may in part explain 
this high finding, but other underlying reasons remain 
unclear. In view of the recent data that all parasite strains 
throughout the world belong to three different clone 
types with different bearing on human disease, of which 
type II strains account for 65% of cases of reactivation of 
toxoplasmosis in AIDS,l* it is tempting to speculate that 
the dramatic difference in the frequency of reactivation 
between Austria and Yugoslavia may be caused by possi- 
ble differences in the geographic distribution of parasite 
strains of different clone types. Regardless of the reasons 
for discrepant findings such as the above, the existence of 
such differences per se indicates the need for local inves- 
tigations. Host genetic factors have also been implicated.” 
Analysis of demographic, epidemiologic, and labora- 
tory parameters widely evaluated as risk factors for the 
development of TE during AIDS in patients in the pre- 
sent study, did not show any significance for age, sex, or 
HIV transmission risk factor, whereas the analysis did 
identify the CD4+ T-cell count and PCP chemoprophy- 
laxis as independent predictors. Non-association of HIV 
transmission risk factors with the development of TE in 
the present series is consistent with the findings in 
Europe, for instance in Belgium,20 whereas it differs from 
the variability found in the United States. Namely, one 
American study showed the highest frequency of TE 
among heterosexuals with no known risk factors (7.5%) 
particularly among black males (12%) followed by intra- 
venous drug users (5.2%),21 and another study showed a 
higher TE rate among intravenous drug users (5.9%) than 
among male homosexuals (4.6%).’ 
The risk associated with the CD4+ T-cell level was the 
highest, as expected, in patients with CD4+ counts below 
50 X 106/L. However, stratification of higher CD4+ counts 
made it possible to observe an increased risk not only at 
counts below, but also (slightly) above 200 X 106/L, gen- 
erally considered not of risk.1,22 However, since this 
occurred exclusively in patients who had not received 
chemoprophylaxis, this finding, taken together with con- 
firmation of the protective effect of systemic PCP pro- 
phylaxis against the development of TE, emphasizes the 
need for early initiation of prophylaxis. 
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